REPL
REPL clinical trials: Replimune Group, Inc.
Every trial on ClinicalTrials.gov where Replimune Group, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 12
- As lead sponsor
- 6
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
REPL on the catalyst calendar · REPL registry changes
- Primary completion Sep 30, 2030Sponsor estimatePhase 3NCT06264180VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]Replimune, Inc. · Advanced MelanomaRecruitingREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 1/Phase 2NCT04349436Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin MalignanciesReplimune, Inc. · Merkel Cell CarcinomaActive, not recruitingREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2030Sponsor estimatePhase 2/Phase 3NCT06581406A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint...Replimune, Inc. · Metastatic Uveal MelanomaRecruitingREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2027Sponsor estimatePhase 2NCT05733598Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCReplimune, Inc. · Hepatocellular CarcinomaRecruitingREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursReplimune, Inc. · Advanced Solid TumorActive, not recruitingREPLLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2026Sponsor estimatePhase 1NCT04336241Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsReplimune, Inc. · CancerActive, not recruitingREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 2NCT03767348Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Replimune, Inc. · Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingREPLLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2025ActualPhase 2NCT05733611RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCReplimune, Inc. · Refractory Metastatic Colorectal CancerTerminatedREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimateNo phase registeredNCT06887348A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3Replimune, Inc. · MelanomaRecruitingREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06590480An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced MelanomaReplimune, Inc. · Advanced MelanomaNo longer availableREPLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2026Sponsor estimatePhase 2NCT05743270Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNReplimune, Inc. · Squamous Cell Carcinoma of Head and NeckWithdrawnREPLLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2025Sponsor estimatePhase 2NCT04050436Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerReplimune, Inc. · Cutaneous Squamous Cell CarcinomaActive, not recruitingREPLLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2027Sponsor estimatePhase 2NCT07059611Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal AdenocarcinomaAbramson Cancer Center at Penn Medicine · Gastric AdenocarcinomaNot yet recruitingREPLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2028Sponsor estimatePhase 2NCT07862530Neoadjuvant RP2 + Nivolumab in Patients With MelanomaYana Najjar · MelanomaCutaneous Melanoma Resectable, MelanomaNot yet recruitingREPLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2029Sponsor estimatePhase 2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS · AngiosarcomaRecruitingREPLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT06623110Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous DiseaseGlenn J. Hanna · High-Risk Oral Precancerous DiseaseRecruitingREPLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2028Sponsor estimateEarly Phase 1NCT06216938RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node MetastasisYana Najjar · MelanomaRecruitingREPLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2025ActualPhase 1/Phase 2NCT06067061"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerInstitut Curie · Triple Negative Breast NeoplasmsTerminatedREPLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner